NCT03687073View on ClinicalTrials.gov

Trial of Indole-3-Carbinol and Silibinin

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 29, 2018

Primary Completion Date

May 7, 2021

Study Completion Date

May 7, 2021

Conditions
Smoking
Interventions
DRUG

Indole-3-Carbinol

Cohorts 2, 3, \& 4: 400 mg PO BID

DRUG

Silibinin

Cohorts 1 \& 4: 720mg

DRUG

Silibin

Cohort 3: 360mg

Trial Locations (1)

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT03687073 - Trial of Indole-3-Carbinol and Silibinin | Biotech Hunter | Biotech Hunter